ZUP1 contributes to the maintenance of cisplatin-resistant growth and is associated with enhanced Treg-related immunosuppressive signaling in NSCLC and may serve as a preliminary natural-product lead for further target- validation and combination studies.
Abstract
Acquired cisplatin resistance limits platinum chemotherapy efficacy in non–small cell lung cancer (NSCLC) and is accompanied by tumor immune microenvironment (TME) remodeling. We integrated public NSCLC single-cell RNA-seq datasets to compare cellular composition and CellChat-inferred communication between post-chemotherapy remission and relapse/resistant tumors, and validated ZUP1 expression and prognostic relevance in TCGA and external cohorts. In cisplatin-resistant A549/R and SK-MES-1/R cells, we generated stable ZUP1 knockdown and assessed proliferation, tumorsphere growth and formation, apoptosis (Annexin V/PI) and BAX/BCL2 expression, and xenograft growth. Tumor cell–peripheral Treg co-cultures were used to quantify the proportion of FOXP3⁺ cells within the gated CD4⁺ population. Natural-product screening was guided by molecular docking, and ZUP1–compound binding was evaluated by surface plasmon resonance (SPR). Peimisine responses were compared between parental and cisplatin-resistant cells. In A549/R cells, experimentally measured viability across a peimisine–cisplatin concentration matrix and cisplatin dose–response curves at fixed peimisine concentrations were used to evaluate changes in cisplatin sensitivity. Resistant tumors exhibited remodeled cellular composition and enhanced intercellular communication, including increased epithelial-to-Treg signaling. ZUP1 was upregulated in resistant models and associated with unfavorable prognosis. ZUP1 knockdown suppressed growth and tumorsphere formation, increased apoptosis, reduced tumorigenicity in vivo, and reduced the proportion of CD4⁺FOXP3⁺ Treg-like cells in co-culture. Peimisine directly bound ZUP1 by SPR, inhibited resistant cell growth, and was associated with lower estimated cisplatin IC₅₀ values in A549/R cells at fixed peimisine concentrations. ZUP1 contributes to the maintenance of cisplatin-resistant growth and is associated with enhanced Treg-related immunosuppressive signaling in NSCLC. Peimisine directly binds ZUP1 and may serve as a preliminary natural-product lead for further target-validation and combination studies.
Targeted silencing of ORC1 effectively reversed resistance both in vitro and in vivo, representing a potential molecular target for overcoming Cisplatin resistance in NSCLC.
Jian-Hui Sheng, Ying-Jian Song· Journal of biochemical and m...· 0 citations
Background Cisplatin resistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC). Exosome-mediated transfer of microRNAs contributes to tumor progression and chemotherapy resistance. However, the role of exosomal miR-22 in cisplatin resistance and its relationship with mouse double minute...
Peng Wang, Jie-Son Jiao, Li-Jun Yu et al.· OncoTargets and Therapy· 0 citations
PTTG1 has been implicated in tumor progression and drug resistance, but its role in acquired anlotinib resistance in non-small cell lung cancer (NSCLC) remains unclear. This study investigated whether PTTG1 contributes to resistance and immune remodeling in NSCLC. We analyzed peripheral blood from NSCLC patients collec...
K. Hui, Yong-Hua Tan, Jia-Wei Song et al.· Biofactors· 0 citations
ABSTRACT Cisplatin (CDDP) resistance constitutes the principal clinical challenge in the treatment of advanced non‐small cell lung cancers (NSCLC). Disturbances in copper metabolism are closely linked with tumor drug resistance. SOX2, a pivotal stemness transcription factor (TF), holds an important role in chemotherapy...
Kun Chen, Fu-Mei He, Ying-Hui Huang et al.· Kaohsiung Journal of Medical...· 0 citations
Non-small cell lung cancer (NSCLC) accounts for ~ 85% of lung cancers and is associated with poor outcomes in advanced stages. Radiotherapy (RT) is central to NSCLC treatment, yet locoregional relapse remains frequent. Increasing evidence indicates that, beyond tumor-intrinsic adaptations, the tumor microenvironm...
Sergio León, N. Otegui, M. Redrado et al.· Journal of Experimental &...· 0 citations
ST6GAL1-mediated α2,6-sialylation of EGFR contributes to the maintenance of CSLC-associated paclitaxel resistance through mTOR-SOX2/BMI1 signaling, which identifies ST6GAL1-dependent EGFR sialylation as a potential therapeutic target in CSLC-associated chemoresistance.
Yu-Xi Yang, Bing-Hui Liang, W. Hong et al.· Cancer Drug Resistance· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.